Biologic Yields Early and Sustained Skin Clearance for Patients with Plaque Psoriasis
A recent poster presentation presented at the Winter Clinical Dermatology Conference demonstrated that secukinumab quickly and effectively improved skin clearance in up to 65% of patients with moderate to severe plaque psoriasis.
For the study, the researchers conducted a post-hoc analysis of 4 clinical trials that included a total of 2396 patients with moderate to severe plaque psoriasis. Of the patients, 691 were randomly assigned to receive 300 mg of secukinumab, 692 were randomly assigned to receive 150 mg of secukinumab, 326 were randomly assigned to receive 50 mg etanercept, and 687 were randomly assigned to receive placebo. Responses were determined using the Investigator’s Global Assessment modified 2011 (IGA mod 2011) and Psoriasis Area and Severity Index (PASI) scores. The researchers evaluated the response rates of patients who achieved IGA mod 2011 0 (clear) or 0/1 (almost clear) over 1 year of treatment.
At the beginning of week 2, patients who received 2 doses of 300 mg of secukinumab showed significantly greater improvements compared with those who received placebo.
Compared with etanercept and placebo, significantly more patients who received either 150 mg or 300 mg of secukinumab achieved IGA mod 2011 0 and 0/1 responses at week 12. These responses were sustained at week 52, with significantly greater responses among patients who received 300 mg of secukinumab compared with those who received etanercept.
Among patients who achieved IGA 0/1 within 12 weeks, the median time to a 50% decrease in mean PASI scores from baseline was 2.6 weeks with 300 mg of secukinumab and 3.1 weeks with 150 mg of secukinumab. Among patients who achieved IGA 0 within 12 weeks, the median time to a 50% decrease in mean PASI scores from baseline were 2.3 weeks and 2.6 weeks for 300 mg of secukinumab and 150 mg of secukinumab, respectively.
In addition, IGA mod 2011 0 at week 52 was achieved by 37.8% of patients who received 300 mg of secukinumab and PASI 100 at week 52 was achieved by 40.8% of patients who received 300 mg of secukinumab. Similarly, 0/1 was achieved by 64.9% of patients and PASI 90 was achieved by 68.1% of patients who received 300 mg of Secukinumab at week 52.
“Secukinumab provides early and sustained skin clearance for patients with moderate-to-severe plaque psoriasis,” the researchers concluded.
Blauvelt A, Armstrong A, Rich P, et al. Secukinumab provides complete or almost-complete psoriasis clearance in moderate-to-severe plaque psoriasis: pooled analysis of 4 phase 3 trials. Presented at: The Winter Clinical Dermatology Conference; January 12-17, 2018; Maui, Hawaii.